Baird Venture Partners

Baird Venture Partners is the venture and expansion capital arm of Robert W. Baird & Co. The Baird Venture Partners team is based in Chicago Illinois and has around $27 million in total assets under management. In 214 Baird closed a fourth venture capital fund at $185 million. The firm is currently seeking opportunities in the life science sector and while Baird has no strict timeline to make investments the group would invest in a new firm within the next 6-9 months if a compelling opportunity was identified. The firm?s equity investments range from $3-1 million but are typically in the $8-1 million range.The firm will only consider investment into US based firms.
Momei Qu
Senior Associate 

Band of Angels

The Band of Angels is a funding organization that was founded in 1994 and it is based in Silicon Valley California. The organization typically provides capital to companies through three programs: The Band of Angels Acorn Fund and The Band of Angels Venture Fund. The group focuses on seed and Series A stage high-tech companies across several industries including life science space. The Band of Angels generally makes investments ranging from $3K to $75k but it often leads a syndication of $2-3million. Acorn Fund which is The Band?s third side fund and was founded in 29 generally makes investments ranging from $1k to $75k. The Band of Angels Venture Fund is a $5 million venture fund which raised in 1999 by The Band of Angels. Initial investment sizes of the fund are typically $3 and can go up to $2.5 million. The Band generally makes around 1 -2 investments per year. The group focuses on companies based in Silicon Valley but it will consider selective opportunities in Los Angles and San Diego areas. The group's portfolio includes biotechnology and medical device companies working with oncology and muscle recovery.
Brian Frenzel
Member 
Michael Bates
Member, Board of Directors 

Baxano Surgical Inc.

Ken Reali
President and CEO 

Baxter Ventures

Baxter Ventures is the strategic venture arm of Baxter International Inc. that was formed in 2011 and is based in Deerfield, Illinois. The firm is currently making equity investments out of a $200 Million fund with allocations generally falling in the $3-$5 million range. The firm is looking in invest in companies who have previously or are currently in the process of securing investment from other institutional investors. The firm is willing to look globally for investment opportunities and plans to make approximately 2 new investments over the next 6-9 months.

Priyanka Rohatgi
Director 

Bayer AG

Website:
www.bayer.com
Chandra Ramanathan
Global Program Head, External Innovation - Life Sciences 

BCAL Diagnostics Pty Ltd Australia

BCAL Diagnostics is a Sydney, Australia based blood diagnostics company with research facilities based in Kentucky, USA.

The BCAL lipid biomarker test is a universal blood test for the effective screening and monitoring of breast cancer.  The BCAL test is being developed to be safe, cost effective, accurate and available to all women regardless of age, race and geographic location.

BCAL Diagnostics is near completion of a 200-patient study. Initial results indicate the BCAL test has a greater than 90% sensitivity and specificity in the diagnosis of invasive ductal carcinoma which is 85% of all breast cancers. 

This will lead to a range of BCAL breast cancer blood tests that can be used across the full breast cancer disease management continuum. from pre-disposition to screening to long term monitoring.

BCAL Diagnostics is now seeking Series B capital of $5-$10M USD to support its global commercialisation activities.

Year Founded
2010
Biotech Subsector
Medtech Subsector
Medtech Phase of Development
Technology Overview
Breast Cancer Associated Lipids
Alliance & Collaborations
Research agreements with Kentucky University USA and Royal Prince Alfred Hospital - NSW Australia
Supporting Metrics or Evidence
80 patient study completed - 200 patient study near completion
Current Financing Needs
$5-$10M Series B
Current Investors
small number of highly sophisticated investors
IP Status
Strong - patents pending
Recent Milestones
Completed 100 sample study with 90% sensitivity and specificity results for the detection of invasive ductal carcinoma
Management Team Highlights
CEO has global diagnostic experience with Roche Diagnostics, Boehringer Mannheim and Cochlear. Management team has extensive lipids in cancer experience with published papers and PhD
Philip Daffas
LinkedIn logo CEO 
BIO

 

Phiilip Daffas is the CEO  of BCAL Diagnostics Pty Ltd a Sydney based diagnostics company. With a career spanning more than 25 years, he brings a wealth of experience in global sales, marketing and business development in the medical devices and diagnostics market. 

 Philip has been based in Sydney since 2001 and has held senior global business leadership positions in Europe, US and Australia with blue chip healthcare companies. He has been instrumental in building businesses, growing market share and developing extensive high-level customer and industry relationships in each sector.

 Roles in Australia have included VP Global Marketing at Cochlear and General Management roles with Roche Diagnostics and Bio-Rad Laboratories and CEO of Applied Physiology, an Australian start up company in the intensive care monitoring sector.

Philip’s earlier experience was gained in Europe with market leaders such as IVAC infusion systems and Shiley cardiopulmonary products. He subsequently joined Boehringer Mannheim, initially in the UK managing their diagnostics business and subsequently was promoted to Global Marketing Director for the Diabetes Care business based in Mannheim, Germany.

In 1997 Philip joined Cochlear in the UK as the European Sales and Marketing Manager and subsequently was promoted to the VP Global Marketing role based in Sydney, Australia.

Graduated in the UK with a BSc and Diploma in Electronic Engineering, Philip also holds an MBA and is a Graduate of the Australian Institute of Company Directors (GAICD).


Peter French
Director & Scientific Advisor 
Dharmica Mistry
Scientific Officer 

BD Medical Surgical Systems

Yuri Haverman
Strategic Innovation 

BDC Venture Capital

Charles Cazabon
Managing Partner 

Becton Dickinson (BD)

BD (Becton Dickinson and Company) based in Franklin Lakes NJ is a leading medical technology company that partners with customers and stakeholders to address many of the world?s most pressing and evolving health needs. Their innovative solutions are focused on improving drug delivery enhancing the diagnosis of infectious diseases and cancers supporting the management of diabetes and advancing cellular research. The firm has nearly 3 associates in 5 countries who strive to fulfill our purpose of ?Helping all people live healthy lives? by advancing the quality accessibility safety and affordability of healthcare around the world. For more information please visit www.bd.com. BD partners with companies from their formation through to commercialization including expansion of operations and channel access. BD considers a variety of engagement models including research collaborations licenses investments and acquisition when partnering with companies aligned with BD?s core businesses and new areas of strategic interest seeking opportunities from around the globe.
Albert Lauritano
Director Strategic Technology Partnerships 

Bell BioSystems

Caleb Bell
Founder & CEO